Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer.

J Clin Pathol 2015 Jun 10;68(6):427-33. Epub 2015 Mar 10.

Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria.

Aims: Tumour markers including carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9) are frequently determined at the time of diagnosis in patients with pancreatic cancer. Several studies indicate a prognostic relevance of these markers in pancreatic cancer, but space for improvement with regard to the predictive accuracy and ability is given. In this work, the main focus is on mathematical combinations of these two tumour markers in order to validate an improvement of prognostic test results in terms of sensitivity and specificity.

Methods: This retrospective study includes 393 patients with pancreatic cancer, who were treated between the years 2005 and 2012 at the Division of Oncology, Medical University of Graz, Austria. The goal of this study was to explore whether an appropriate combination of two tumour markers leads to a statistically significant improvement of the prognostic prediction.

Results: Receiver operating characteristic curves comparison analyses with the classification variable cancer-specific survival showed that the mathematical product of two tumour markers (TM(product)= (CEA×CA19-9); area under the curve (AUC)=0.727; 95% CI 0.680 to 0.770) is significantly better than CEA alone (AUC=0.644; 95% CI 0.594 to 0.691; p=0.003) but not significant compared with CA19-9 (AUC=0.710; 95% CI 0.662 to 0.754; p=0.1215). A linear combination of CEA and CA19-9 (TM(linear)=(85×CEA+CA19-9); AUC=0.748; 95% CI 0.702 to 0.790) is significantly better than CEA (p<0.0001) as well as CA19-9 alone (p=0.0304).

Conclusions: Mathematical combinations of pretherapeutic tumour markers CEA and CA19-9 are feasible and can significantly improve the prognostic prediction in patients with pancreatic cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2014-202451DOI Listing
June 2015
6 Reads

Publication Analysis

Top Keywords

tumour markers
20
pancreatic cancer
16
patients pancreatic
12
better cea
8
improvement prognostic
8
cea ca19-9
8
combination tumour
8
markers
6
cea
5
markers leads
4
appropriate combination
4
study explore
4
leads statistically
4
goal study
4
austria goal
4
explore appropriate
4
receiver operating
4
curves comparison
4
comparison analyses
4
analyses classification
4

References

(Supplied by CrossRef)
Cancer statistics, 2014
Siegel et al.
CA Cancer J Clin 2014

Howlader et al.
2012
The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates
Poruk et al.
Curr Mol Med 2013
Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study
Inal et al.
J BUON 2012
Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis
Papadoniou et al.
Anticancer Res 2008

Similar Publications